Yes, variants in the GLP1R gene (e.g., rs6923761) have been associated with differences in weight loss response to GLP-1 medications in clinical studies
What they may do, through weight loss and metabolic improvement, is: Reduce the fat pad at the base of the penis Improve blood flow and erection quality Improve hormonal and cardiovascular health* *which also helps to alleviate heart disease, cardiovascular disease and other related health conditions In other words, these medicines may change how much of the penis is visible and how well it functions, not the size of the organ itself
10.2337/dc10-2415 130 ZhengH.CaiL.RinamanL
What is established is that its pharmacokinetic profile supports once-weekly dosing, achieved through a C20 fatty diacid moiety that binds to serum albumin the same strategy used by semaglutide and tirzepatide, both of which have half-lives of approximately 5-7 days
Just as importantly, you deserve to feel confident while on your journey